Orakl
37 employees on LinkedIn · 6 known investors
Orakl Oncology, a spin-off from Gustave Roussy, builds an AI-and-biology platform that grows patient-derived tumor organoids and enriches them with genomic, transcriptomic, phenotypic, and clinical data to predict drug response and clinical trial outcomes. It offers O-Predict for anticipating clinical endpoints and biomarkers and O-Target for therapeutic target discovery, serving biopharma companies in oncology drug discovery and development.
Founders & leadership
DP
Diane-Laure PagèsinCo-founder, COO
Investors · 6
.jpeg){kind=logo}
In the news
Frequently asked questions
- What does Orakl do?
- Orakl Oncology, a spin-off from Gustave Roussy, builds an AI-and-biology platform that grows patient-derived tumor organoids and enriches them with genomic, transcriptomic, phenotypic, and clinical data to predict drug response and clinical trial outcomes. It offers O-Predict for anticipating clinical endpoints and biomarkers and O-Target for therapeutic target discovery, serving biopharma companies in oncology drug discovery and development.
- Who founded Orakl?
- Orakl was founded by Diane-Laure Pagès.
- Who are Orakl's investors?
- Orakl's investors include HCVC, Sista, Verve Ventures, Bpifrance, Singular, Speedinvest.